MeiraGTx Holdings plc

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.



https://finviz.com/published_idea.ashx?t...074922068i

BARRON´S
This Small Biotech Is Partnering With Johnson & Johnson. The Stock Could More Than Double.
Last Updated: Oct. 15, 2021 at 9:14 p.m.
ET First Published: Oct. 15, 2021 at 8:00 p.m. ET

Since the excitement of multibillion-dollar acquisitions of gene-therapy firms by Novartis and Roche Holding a few years ago, many gene-therapy stocks have sunk to small-cap valuations. Among them is MeiraGTx Holdings, shares of which fell from a 2019 peak of $30 to a recent $14, leaving its market capitalization below $600 million—and only a half-dozen analysts paying it heed.

That’s an opportunity for investors. MeiraGTx (ticker: MGTX) has several treatments in clinical trials, some of the industry’s best manufacturing centers, and a deep-pocketed partner in Johnson & Johnson (JNJ). And MeiraGTx says it has a technology that could revolutionize genetic medicine by regulating the artificial genes that gene-transfer therapies place in patients’ cells. MeiraGTx has been quietly working on that technology for six years and hasn’t revealed much data. But at today’s stock price, it could be a good time for investors with an appetite for risk to invest...............

https://www.marketwatch.com/articles/bio...=bigcharts